Astrazeneca PLC (AZN): Price and Financial Metrics


Astrazeneca PLC (AZN)

Today's Latest Price: $52.61 USD

0.01 (0.02%)

Updated Nov 27 1:00pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • With a market capitalization of $138,048,640,000, Astrazeneca Plc has a greater market value than 98.59% of US stocks.
  • The price/operating cash flow metric for Astrazeneca Plc is higher than 86.63% of stocks in our set with a positive cash flow.
  • The volatility of Astrazeneca Plc's share price is greater than that of merely 10.3% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are AMGN, LLY, SAP, SNY, and TXN.
  • AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to www.astrazeneca.com.

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $52.61 52-week high $64.94
Prev. close $52.60 52-week low $36.15
Day low $51.44 Volume 14,783,100
Day high $52.77 Avg. volume 5,237,630
50-day MA $54.04 Dividend yield 1.67%
200-day MA $52.20 Market Cap 138.08B

Astrazeneca PLC (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$52.61$14.82 -73%

Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 5.75 years, is -0.09% -- higher than only 14.77% of stocks in our DCF forecasting set.
  • As a business, AZN is generating more cash flow than 89.13% of positive cash flow stocks in the Healthcare.
  • Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 16.49% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-74%
1%-73%
2%-73%
3%-73%
4%-73%
5%-72%

GMED, NRC, BAX, CNC, and MTD can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


AZN Latest News Stream


Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

AstraZeneca’s Farxiga nabs accelerated review in U.S. for kidney disease

The FDA has granted Breakthrough Therapy Designation to AstraZeneca’s (AZN) Farxiga for the treatment of patients with chronic kidney disease, with and without type-2 diabetes.Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the...

Seeking Alpha | October 2, 2020

Study of AstraZeneca COVID-19 vaccine resumes in Japan

Following a review of safety data by an independent committee, a Phase 1/2 clinical trial evaluating AstraZeneca's (AZN) COVID-19 vaccine candidate, AZD1222, has resumed in Japan following earlier restarts in the U.K., Brazil, South Africa and India.The U.S. study has yet to resume....

Seeking Alpha | October 2, 2020

Canada to Begin Review of AstraZeneca COVID-19 Vaccine Amid Immunization Skepticism

No summary available.

UrduPoint | October 2, 2020

AstraZeneca Working With Russian Partners for Delivery of COVID-19 Vaccine- Representative

No summary available.

UrduPoint | October 2, 2020

News24.com | Leading Covid-19 vaccine trial resumes in Japan but not US

Trials on the coronavirus vaccine developed by AstraZeneca and Oxford University have resumed in Japan but not the United States, where the pharmaceutical giant is working with regulators, a statement released said.

News24 | October 2, 2020

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 4.88%
3-mo -6.05%
6-mo -3.10%
1-year 11.55%
3-year 76.61%
5-year 82.86%
YTD 8.46%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6779 seconds.